Aquestive Therapeutics, Inc. (AQST) Reaches $8.66 After 3.00% Down Move; Atlanticus Holdings (ATLC)’s Sentiment Is 2.17

Atlanticus Holdings Corporation (NASDAQ:ATLC) Logo

The stock of Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a huge mover today! The stock decreased 1.03% or $0.09 during the last trading session, reaching $8.66. About 858,210 shares traded or 102.13% up from the average. Aquestive Therapeutics, Inc. (NASDAQ:AQST) has declined 77.36% since December 4, 2018 and is downtrending. It has underperformed by 77.36% the S&P500.The move comes after 5 months negative chart setup for the $216.88M company. It was reported on Dec, 4 by Barchart.com. We have $8.40 PT which if reached, will make NASDAQ:AQST worth $6.51 million less.

Atlanticus Holdings Corp (ATLC) investors sentiment increased to 2.17 in Q2 2019. It’s up 0.97, from 1.2 in 2019Q1. The ratio improved, as 6 funds increased and opened new positions, while 5 decreased and sold equity positions in Atlanticus Holdings Corp. The funds in our database now own: 2.07 million shares, down from 2.08 million shares in 2019Q1. Also, the number of funds holding Atlanticus Holdings Corp in top ten positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 2 Increased: 4 New Position: 2.

Atlanticus Holdings Corporation provides credit and related financial services and products to financially underserved consumer credit market in the United States. The company has market cap of $126.96 million. It operates in two divisions, Credit and Other Investments, and Auto Finance. It has a 2.54 P/E ratio. The Credit and Other Investments segment originates a range of consumer loan products, such as retail credit, personal loans, and credit cards through various channels, including retail point-of-sale, direct mail solicitation, Internet marketing, and partnerships with third parties; and offers point-of-sale financing by partnering with retailers and service providers to provide credit to their clients for the purchase of various goods and services.

The stock increased 2.43% or $0.19 during the last trading session, reaching $8. About 18,942 shares traded. Atlanticus Holdings Corporation (ATLC) has risen 169.71% since December 4, 2018 and is uptrending. It has outperformed by 169.71% the S&P500. Some Historical ATLC News: 20/04/2018 DJ Atlanticus Holdings Corp, Inst Holders, 1Q 2018 (ATLC)

More notable recent Atlanticus Holdings Corporation (NASDAQ:ATLC) news were published by: Finance.Yahoo.com which released: “The Atlanticus Holdings (NASDAQ:ATLC) Share Price Has Gained 108%, So Why Not Pay It Some Attention? – Yahoo Finance” on July 31, 2019, also Seekingalpha.com with their article: “Triple-S Management leads financial gainers; Realogy Holdings and Rand Capital among losers – Seeking Alpha” published on November 07, 2019, Finance.Yahoo.com published: “Does Atlanticus Holdings Corporation’s (NASDAQ:ATLC) CEO Pay Compare Well With Peers? – Yahoo Finance” on October 29, 2019. More interesting news about Atlanticus Holdings Corporation (NASDAQ:ATLC) were released by: Globenewswire.com and their article: “Fortiva® Retail Credit Expands Partnership with American Signature Furniture to Offer Second Look Financing Solutions Nationwide – GlobeNewswire” published on November 12, 2019 as well as Globenewswire.com‘s news article titled: “ATLANTICUS HOLDINGS CORPORATION APPOINTS AKBAR RIZVI AS SENIOR VICE PRESIDENT OF MARKETING – GlobeNewswire” with publication date: September 27, 2019.

Zazove Associates Llc holds 0.05% of its portfolio in Atlanticus Holdings Corporation for 875 shares. Css Llc Il owns 74,760 shares or 0.02% of their US portfolio. Moreover, Bank Of New York Mellon Corp has 0% invested in the company for 10,155 shares. The New York-based Blackrock Inc. has invested 0% in the stock. Bridgeway Capital Management Inc, a Texas-based fund reported 62,112 shares.

More notable recent Aquestive Therapeutics, Inc. (NASDAQ:AQST) news were published by: Nasdaq.com which released: “All You Need to Know About Aquestive Therapeutics (AQST) Rating Upgrade to Buy – Nasdaq” on November 11, 2019, also Nasdaq.com with their article: “Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates – Nasdaq” published on November 05, 2019, Nasdaq.com published: “Healthcare Stocks That Hit New Highs (XENE, AQST, DRNA…) – Nasdaq” on December 03, 2019. More interesting news about Aquestive Therapeutics, Inc. (NASDAQ:AQST) were released by: Nasdaq.com and their article: “Today’s Top 5 Gainers In Healthcare Sector (CABA, INMD, AQST…) – Nasdaq” published on November 11, 2019 as well as Globenewswire.com‘s news article titled: “Aquestive Therapeutics to Host Investor & Analyst Libervantâ„¢ (diazepam) Buccal Film Update Forum at American Epilepsy Society 2019 Annual Meeting – GlobeNewswire” with publication date: December 04, 2019.

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company has market cap of $216.88 million. The Company’s products are developed using its PharmFilm technology. It currently has negative earnings. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.